Bone mineral density in midlife long-term users of hormonal contraception in South Africa: relationship with obesity and menopausal status
Open Access
- 10 April 2018
- journal article
- research article
- Published by Springer Nature in Women's Midlife Health
- Vol. 4 (1) , 6
Abstract
In South Africa, hormonal contraception is widely used in women over the age of 40 years. One of these methods and the most commonly used is depot-medroxyprogesterone acetate (DMPA) which has been found to have a negative effect on bone mass. Limited information is available on the effect of norethisterone enanthate (NET-EN) on bone mass, and combined oral contraceptives (COCs) have not been found to be associated with loss of bone mass. The aim of this study was to investigate bone mineral density (BMD) in pre and perimenopausal women (40–49 years) in relation to use of DMPA, NET-EN and COCs for at least 12 months preceding recruitment into the study and review associations with body mass index (BMI) and menopausal status. One hundred and twenty seven users of DMPA, 102 NET-EN users and 106 COC users were compared to 161 nonuser controls. Menopausal status was assessed, BMI and forearm BMD was measured at the distal radius using dual X-ray absorptiometry. Comparison analysis was conducted at baseline and 2.5 years. There was no significant difference in BMD between the four contraceptive user groups (p = 0.26) with and without adjustment for age at baseline or at 2.5 years (p = 0.52). The BMD was found to be significantly associated with BMI (p = < 0.0001) with an increase of one unit of BMI translating to an increase of 0.0044 g/cm2 in radius BMD. Follicle stimulating hormone (FSH) level ≥ 25.8 mIU/mL was associated with a decrease of 0.017 g/cm2 in radius BMD relative to women with FSH < 25.8 mIU/mL. Significant interaction between FSH and BMI in their effect on BMD was observed (p = .006). This study found no evidence that long-term use of DMPA, NET-EN and COCs affects forearm BMD in this population at baseline or after 2.5 years of follow-up. This study also reports the complex relationship and significant interaction between FSH and BMI in their effect on BMD. BMD research in older women needs to ensure that women are assessed for menopausal status and BMI.Keywords
Funding Information
- World Health Organization
This publication has 24 references indexed in Scilit:
- Is obesity in women protective against osteoporosis?Diabetes, Metabolic Syndrome and Obesity, 2011
- Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetateContraception, 2008
- Bone status after cessation of use of injectable progestin contraceptivesContraception, 2007
- Progestogen-only contraception and bone mineral density: a systematic reviewContraception, 2006
- Bone mineral density in women aged 40–49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraceptionContraception, 2005
- Discordance Between Changes in Bone Mineral Density Measured at Different Skeletal Sites in Perimenopausal Women—Implications for Assessment of Bone Loss and Response to Therapy: The Danish Osteoporosis Prevention StudyJournal of Bone and Mineral Research, 2001
- Steroid hormone contraception and bone mineral density: a cross-sectional study in an international populationObstetrics & Gynecology, 2000
- Bone mineral density in women using depot medroxyprogesterone acetate for contraceptionObstetrics & Gynecology, 1999
- Bone density in long term users of depot medroxyprogesterone acetateBJOG: An International Journal of Obstetrics & Gynaecology, 1998
- Bone density at various sites for prediction of hip fracturesThe Lancet, 1993